Literature DB >> 16371043

Cell loss and recovery in umbilical cord blood processing: a comparison of postthaw and postwash samples.

Vincent Laroche1, David H McKenna, Gary Moroff, Therese Schierman, Diane Kadidlo, Jeffrey McCullough.   

Abstract

BACKGROUND: Engraftment after umbilical cord blood (UCB) transplantation is highly dependent on nucleated cell (NC) and CD34+ cell content. Current standard postthaw (PT) processing includes a wash step to remove dimethyl sulfoxide (DMSO), lysed red cells, and stroma. The contribution of the wash step to cell loss and ultimately the dose of cells available for transplant have yet to be systematically reported. This study examines the effect of the wash step as well as that of PT storage on various quality control variables of UCB units. STUDY DESIGN AND METHODS: Ten units were thawed and washed based on the New York Blood Center method. Samples were removed from each unit at six time points: prefreeze (PF), immediately PT, immediately postwash (PW), and 1, 2, and 5 hours PW. On each sample, total nucleated cell (TNC) count, CD34+ cell enumeration, colony-forming unit (CFU)-granulocyte-macrophage, and viability assays (fluorescence microscopy [acridine orange/propidium iodide, or AO/PI] and flow cytometry [7-aminoactinomycin]) were obtained.
RESULTS: TNC counts decreased PT and at subsequent time points; the PT TNC recovery was 89 percent compared to 82 percent PW (p < 0.01). TNC recovery decreased to 90 percent of PW (82% of PT) values (p < 0.01) and 83 percent of PW (76% of PT) values (p < 0.001), at 2 and 5 hours PW, respectively. CD34+ cell loss PT was not significant. Viability by AO/PI decreased PT and plateaued over time. In contrast, viability by flow cytometry remained higher and increased slightly over time. CFUs were significantly lower PT, recovering PW.
CONCLUSIONS: Our data indicate that the thawing and washing results in a substantial loss of cells, with TNC loss approaching 20 percent when compared with PF counts; the wash step was responsible for nearly half of the cell loss. The reduced PT viability was expected. Elapse of time PW resulted in further loss of NCs but no detectable significant changes in CD34+ cell content and viability and/or CFU.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16371043     DOI: 10.1111/j.1537-2995.2005.00638.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  22 in total

1.  Quality of long-term cryopreserved umbilical cord blood units for hematopoietic cell transplantation.

Authors:  Shohei Yamamoto; Hirokazu Ikeda; Daisuke Toyama; Mayumi Hayashi; Kousuke Akiyama; Manabu Suzuki; Yutaka Tanaka; Tsuneki Watanabe; Yoko Fujimoto; Ichirou Hosaki; Hirokazu Nishihira; Keiichi Isoyama
Journal:  Int J Hematol       Date:  2011-01-05       Impact factor: 2.490

2.  A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies.

Authors:  U Sobol; A Go; S Kliethermes; S Bufalino; T Rodriguez; S Smith; M Parthasarathy; P Stiff
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

3.  Comparison of pre-cryopreserved and post-thaw-and-wash-nucleated cell count on major outcomes following unrelated cord blood transplant in children.

Authors:  Meghann Pine McManus; Li Wang; Cassie Calder; Becky Manes; Misty Evans; Kathryn Bruce; Richard H Ho; Jennifer Domm; Haydar Frangoul
Journal:  Pediatr Transplant       Date:  2012-04-26

4.  Umbilical cord blood processing using Prepacyte-CB increases haematopoietic progenitor cell availability over conventional Hetastarch separation.

Authors:  C Basford; N Forraz; S Habibollah; K Hanger; C P McGuckin
Journal:  Cell Prolif       Date:  2009-09-15       Impact factor: 6.831

5.  Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.

Authors:  Sandhya R Panch; Sandeep K Srivastava; Nasha Elavia; Andrew McManus; Shutong Liu; Ping Jin; Steven L Highfill; Xiaobai Li; Pradeep Dagur; James N Kochenderfer; Terry J Fry; Crystal L Mackall; Daniel Lee; Nirali N Shah; David F Stroncek
Journal:  Mol Ther       Date:  2019-05-30       Impact factor: 11.454

6.  Safety and feasibility for pediatric cardiac regeneration using epicardial delivery of autologous umbilical cord blood-derived mononuclear cells established in a porcine model system.

Authors:  Susana Cantero Peral; Harold M Burkhart; Saji Oommen; Satsuki Yamada; Scott L Nyberg; Xing Li; Patrick W O'Leary; Andre Terzic; Bryan C Cannon; Timothy J Nelson
Journal:  Stem Cells Transl Med       Date:  2015-01-05       Impact factor: 6.940

7.  The cord blood separation league table: a comparison of the major clinical grade harvesting techniques for cord blood stem cells.

Authors:  Christina Basford; Nicolas Forraz; Saba Habibollah; Kendal Hanger; Colin McGuckin
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

8.  The Functional Effect of Repeated Cryopreservation on Transduced CD34+ Cells from Patients with Thalassemia.

Authors:  Garyfalia Karponi; Penelope-Georgia Papayanni; Fani Zervou; Asimina Bouinta; Achilles Anagnostopoulos; Evangelia Yannaki
Journal:  Hum Gene Ther Methods       Date:  2018-08-30       Impact factor: 2.396

9.  "No wash" albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment.

Authors:  Parastoo B Dahi; Doris M Ponce; Sean Devlin; Katherine L Evans; Marissa N Lubin; Anne Marie Gonzales; Joann Tonon; Richard Meagher; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-18       Impact factor: 5.742

10.  A "no-wash" albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions.

Authors:  Juliet N Barker; Michelle Abboud; Robert D Rice; Rebecca Hawke; Allison Schaible; Glenn Heller; Vincent La Russa; Andromachi Scaradavou
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-25       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.